Experts on myelodysplastic syndrome provide comprehensive insights on the evolving disease and treatment landscape.
EP. 1: Diagnosing Lower-Risk MDS
Experts review best practices for identifying and diagnosing patients with lower-risk MDS.
EP. 2: Classifying MDS: Updated WHO and ICC Guidelines
Drs Safah and Koprivnikar review updates made to the WHO and ICC guidelines when classifying MDS as well as discussing the impact of molecular alterations when treating MDS.
EP. 3: Risk Stratification Tools for MDS: IPSS, IPSS-R, IPSS-M
Hana Safah, MD explains how the risk stratification for MDS has evolved over time and provides an in-depth of the current risk stratification tools, IPSS, IPSS-R and IPSS-M.
EP. 4: Importance of Early Detection and Unmet Needs in MDS
Clinicians discuss the importance of early detection in patients with MDS as well as providing insights into some of the unmet needs in MDS, such as a better understanding of the role of molecular alterations and its specific impact in MDS.
EP. 5: Lower-Risk MDS: Treatment Goals and Options
Insights into treatment goals and review of the current treatment landscape for lower-risk MDS.
EP. 6: Choosing Treatment for Lower-Risk MDS
Experts comment on factors that influence their decision-making when treating patients with lower-risk MDS.
EP. 7: Role of Stem Cell Transplant in MDS
Dr Hana Safah discusses the role of stem cell transplant and reviews the eligibility criteria.
EP. 8: MEDALIST: Clinical Implications in Lower-Risk MDS
Clinicians review the MEDALIST trial, which evaluated luspatercept in the second-line setting and comment on updated data from MEDALIST that was recently presented at the annual ASH 2023 meeting.
EP. 9: Imetelstat and Canakinumab in Lower-Risk MDS
Drs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.
2 Commerce Drive Cranbury, NJ 08512